First-Line Pembrolizumab Shows Substantial Activity in Advanced Bladder Cancer
October 10th 2016Early results from a pre-planned interim analysis in the KEYNOTE-052 phase II trial of first-line pembrolizumab in cisplatin-ineligible patients with metastatic urothelial cancer demonstrated antitumor activity and a favorable response rate.
Ceritinib Establishes PFS Advantage in Second-Line ALK+ NSCLC
Progression-free survival was more than 3 times longer with ceritinib (Zykadia) than with chemotherapy, the current second-line standard, in patients with advanced ALK-positive non–small cell lung cancer who progressed after first-line crizotinib.
Second-Line Nivolumab Data in mUC Show Efficacy as FDA Considers Approval
October 9th 2016Safety, efficacy, and biomarker results from the phase II CheckMate-275 trial of the PD-1 inhibitor nivolumab (Opdivo) that support FDA and European Medicines Agency applications were reported at the 2016 ESMO Congress.
Dr. Braghiroli on Clinical Characteristics of NRAS-Mutant CRC
October 9th 2016Maria Ignez Braghiroli, MD, medical oncologist, Instituto do Câncer do Estado de São Paulo, discusses clinical characteristics and outcomes of patients with NRAS-mutant metastatic colorectal cancer (mCRC) during an interview at the 2016 ESMO Congress.
Regorafenib Shows Clinical Benefit in Patients with HCC Who Progress on Sorafenib
October 8th 2016The oral multikinase inhibitor regorafenib (Stivarga) has the potential to become the standard of care as second-line treatment in patients with previously treated hepatocellular carcinoma who are unsuitable for loco-regional therapy and have progressed on sorafenib.
Ribociclib Leads to Major PFS Increase in HR+ Metastatic Breast Cancer
Postmenopausal women with hormone receptor-positive metastatic breast cancer had significant slowing of disease progression with the addition of the investigational cyclin-dependent kinase 4/6 inhibitor ribociclib to endocrine therapy.
Dr. Llombart-Cussac on the CASCADE Study in Metastatic Breast Cancer
October 8th 2016Antonio Llombart-Cussac, MD, PhD, medical oncologist, chairman, Medical Oncology Service, University Hospital Arnau de Vilanova in Valencia, Spain, discusses the CASCADE study, which assessed declines in treatment efficacy over time in patients with metastatic breast cancer, during an interview at the 2016 ESMO Congress.
Targeting Src Adds No Benefit in VEGF-Resistant Metastatic Renal Cell Carcinoma
Adding saracatinib to vascular endothelial growth factor (VEGF)-targeted therapy did not improve response rates or overall survival while adding to toxicity in VEGF-resistant metastatic renal cell carcinoma